Context Therapeutics, Inc. (CNTX)

NASDAQ: CNTX · Delayed Price · USD
1.95
-0.16 (-7.58%)
At close: Jan 27, 2022 4:00 PM
1.99
0.04 (2.05%)
Pre-market:Jan 28, 2022 5:36 AM EST
Market Cap19.90M
Revenue (ttm)n/a
Net Income (ttm)4.93M
Shares Out10.21M
EPS (ttm)0.48
PE Ratio4.04
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume687,566
Open2.12
Previous Close2.11
Day's Range1.93 - 2.12
52-Week Range1.83 - 10.87
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About CNTX

Context Therapeutics® is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers, which include, but are not limited to, breast, ovarian and endometrial cancer. Our first program and lead product candidate, onapristone extended release (“ONA-XR”), builds upon a foundation of successful drug development by our management team and advisors in the field of female hormone-dependen...

IndustryPharmaceuticals
IPO DateOct 20, 2021
CEOMartin Lehr
Employees1
Stock ExchangeNASDAQ
Ticker SymbolCNTX
Full Company Profile

Financial Performance

Financial Statements

News

Context Therapeutics® Strengthens Research & Development Team

Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D

3 weeks ago - GlobeNewsWire

Context Therapeutics® to Participate in Two January 2022 Investor Conferences

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women's oncology company developing small molecule and immunotherapy treatments f...

3 weeks ago - GlobeNewsWire

CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Therapeutics Soaring Today

Context Therapeutics (CNTX) stock is rising higher on Friday thanks to results from a Phase 0 breast cancer clinical trial. The post CNTX Stock: The Breast Cancer Clinical Trial Data That Has Context Th...

1 month ago - InvestorPlace

Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer

Context Therapeutics Inc (NASDAQ: CNTX) posted data from the window-of-opportunity trial of onapristone extended-release (ONA-XR) in postmenopausal patients with progesterone receptor-positive (PR+) ear...

1 month ago - Benzinga

Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Sy...

Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer

1 month ago - GlobeNewsWire

Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement

PHILADELPHIA, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women's oncology company developing small molecule and immunotherapy...

1 month ago - GlobeNewsWire

Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results

Entered into $31.25 million Private Placement Agreement

1 month ago - GlobeNewsWire

Context Therapeutics Shares Drop After Raising $31M Via Equity

Newly listed Context Therapeutics Inc (NASDAQ: CNTX) has announced a private placement of $31.25 million. The placement includes 5 million shares together with warrants to purchase 5 million shares.

1 month ago - Benzinga

Context Therapeutics Inc. Announces $31.25 Million Private Placement

PHILADELPHIA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women's oncology company developing small molecule and immunotherapy...

1 month ago - GlobeNewsWire

Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium

Primary results from ONAWA (SOLTI-1802) trial of ONA-XR in early breast cancer to be presented in addition to updates from ongoing clinical trials of ONA-XR in metastatic breast cancer Primary results f...

2 months ago - GlobeNewsWire

Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer

Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO

2 months ago - GlobeNewsWire

Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metas...

Trial Will Evaluate Progesterone Receptor ONA-XR in Combination with Estrogen Receptor Antagonist to Determine Potential of Complete Hormone Blockade on Metastatic Breast Cancer Outcomes Trial Will Eval...

3 months ago - GlobeNewsWire

Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter's Over-all...

PHILADELPHIA, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the “Company”) (Nasdaq: CNTX), a women's oncology company developing advanced small molecule and immunotherapy treatments to tr...

3 months ago - GlobeNewsWire

Context Therapeutics® Announces Pricing of Initial Public Offering

PHILADELPHIA, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the “Company”) (Nasdaq: CNTX), a women's oncology company developing advanced small molecule and immunotherapy treatments to tr...

3 months ago - GlobeNewsWire